Blood test aids in predicting lung cancer mortality risk
A blood-based test developed by researchers at The University of Texas MD Anderson Cancer Center can predict an individual’s risk of...
Largest-ever atlas of normal breast cells brings...
A new study led by researchers at The University of Texas MD Anderson Cancer, University of California, Irvine and Baylor College of...
MD Anderson Research Highlights for June 27, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
New understanding of why kidney cancers become metastatic...
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC),...
MD Anderson and Ochsner Health announce partnership to...
The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create...
Mutant KRAS regulates Y chromosome gene in colorectal...
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in...
MD Anderson and Replay announce FDA clearance of IND...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
Adagrasib effective for patients with KRAS G12C-mutant lung...
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity...
Study brings new understanding of multiple myeloma evolution
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of...
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
ASCO: Axi-cel significantly improves survival in patients...
ABSTRACT: LBA107
CHICAGO – Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall...
ASCO: Targeted therapy achieves responses across multiple...
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center...
ASCO: HER2-targeted antibody drug conjugate shows strong...
ABSTRACT: LBA3000
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed...
ASCO: Targeted therapy induces responses in HER2-amplified...
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory...